Rosetta Genomics has announced the commercial launch of OncoGxOne, Admera Health’s next-generation sequencing panel that detects genetic alterations implicated in cancer to provide clear, concise, and actionable clinical recommendations from a single test. Rosetta said OncoGxOne interrogates all types of genomic aberrations in 64 genes, specifically 56 related to cancer targeted therapy and eight related […]
